See more : Balchem Corporation (BCPC) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Techne Corporation (TECH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Techne Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vitro, S.A.B. de C.V. (VITROA.MX) Income Statement Analysis – Financial Results
- M.K. Real Estate Development Public Company Limited (MK.BK) Income Statement Analysis – Financial Results
- Orange Electronic Co., Ltd. (4554.TWO) Income Statement Analysis – Financial Results
- Cyient DLM Limited (CYIENTDLM.NS) Income Statement Analysis – Financial Results
- Berjaya Food Bhd (5196.KL) Income Statement Analysis – Financial Results
Bio-Techne Corporation (TECH)
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.16B | 1.14B | 1.11B | 931.03M | 738.69M | 714.01M | 642.99M | 563.00M | 499.02M | 452.25M | 357.76M | 310.58M | 314.56M | 289.96M | 269.05M | 263.96M | 257.42M | 223.48M | 202.62M | 178.65M | 161.26M | 145.01M | 130.90M | 115.36M | 103.84M | 90.90M | 67.30M | 60.90M | 54.60M | 47.70M | 40.30M | 28.70M | 22.30M | 19.30M | 15.70M | 12.50M |
| Cost of Revenue | 389.34M | 366.89M | 349.10M | 298.18M | 255.50M | 240.52M | 210.85M | 188.46M | 162.36M | 144.97M | 106.35M | 79.47M | 78.76M | 65.03M | 54.46M | 55.49M | 52.89M | 46.67M | 45.72M | 36.81M | 34.89M | 35.40M | 32.51M | 28.42M | 23.33M | 25.00M | 17.80M | 17.00M | 17.10M | 16.80M | 15.20M | 11.80M | 9.60M | 8.90M | 7.30M | 6.10M |
| Gross Profit | 769.73M | 769.82M | 756.50M | 632.85M | 483.19M | 473.49M | 432.14M | 374.54M | 336.66M | 307.28M | 251.41M | 231.11M | 235.80M | 224.94M | 214.58M | 208.47M | 204.53M | 176.82M | 156.90M | 141.84M | 126.37M | 109.61M | 98.39M | 86.93M | 80.51M | 65.90M | 49.50M | 43.90M | 37.50M | 30.90M | 25.10M | 16.90M | 12.70M | 10.40M | 8.40M | 6.40M |
| Gross Profit Ratio | 66.41% | 67.72% | 68.42% | 67.97% | 65.41% | 66.31% | 67.21% | 66.53% | 67.46% | 67.94% | 70.27% | 74.41% | 74.96% | 77.57% | 79.76% | 78.98% | 79.45% | 79.12% | 77.44% | 79.39% | 78.37% | 75.59% | 75.17% | 75.36% | 77.53% | 72.50% | 73.55% | 72.09% | 68.68% | 64.78% | 62.28% | 58.89% | 56.95% | 53.89% | 53.50% | 51.20% |
| Research & Development | 96.66M | 92.49M | 87.14M | 70.60M | 65.19M | 62.41M | 55.33M | 53.51M | 45.19M | 40.85M | 30.95M | 29.26M | 27.91M | 25.99M | 25.12M | 23.56M | 22.39M | 20.08M | 18.83M | 18.38M | 20.77M | 20.58M | 17.47M | 14.52M | 11.20M | 12.00M | 10.60M | 11.70M | 10.40M | 8.60M | 6.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 396.83M | 352.44M | 339.00M | 289.92M | 240.88M | 236.87M | 240.64M | 153.33M | 140.88M | 119.40M | 60.72M | 43.38M | 41.68M | 35.90M | 32.18M | 33.16M | 36.72M | 30.97M | 27.60M | 24.48M | 21.73M | 19.38M | 19.55M | 17.71M | 17.32M | 16.90M | 15.40M | 14.60M | 13.00M | 11.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 25.94M | 33.77M | 35.03M | 19.70M | 27.49M | 0.00 | 45.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 396.83M | 378.38M | 372.77M | 324.95M | 260.58M | 264.36M | 240.64M | 199.24M | 140.88M | 119.40M | 60.72M | 43.38M | 41.68M | 35.90M | 32.18M | 33.16M | 36.72M | 30.97M | 27.60M | 24.48M | 21.73M | 19.38M | 19.55M | 17.71M | 17.32M | 16.90M | 15.40M | 14.60M | 13.00M | 11.20M | 9.20M | 8.70M | 7.60M | 7.70M | 6.60M | 5.60M |
| Other Expenses | 0.00 | 39.72M | 4.80M | -89.12M | 119.06M | -34.70M | -10.23M | -8.56M | -3.11M | 7.14M | -1.04M | 830.00K | 693.00K | 0.00 | 960.00K | 960.00K | 1.14M | 1.61M | 1.97M | 1.22M | 1.60M | 1.94M | 8.55M | 8.89M | 12.65M | 11.90M | 2.30M | 2.30M | 1.90M | 1.70M | 11.00M | 10.00M | 8.60M | 8.20M | 6.90M | 5.80M |
| Operating Expenses | 563.04M | 470.87M | 459.91M | 395.55M | 325.78M | 326.77M | 295.97M | 252.76M | 186.07M | 160.25M | 91.66M | 74.83M | 71.72M | 61.88M | 58.26M | 57.69M | 60.24M | 52.66M | 48.40M | 44.08M | 44.10M | 41.90M | 45.57M | 41.13M | 41.16M | 40.80M | 28.30M | 28.60M | 25.30M | 21.50M | 17.50M | 10.00M | 8.60M | 8.20M | 6.90M | 5.80M |
| Cost & Expenses | 952.37M | 837.76M | 809.01M | 693.74M | 581.27M | 567.29M | 506.82M | 441.22M | 348.43M | 305.22M | 198.01M | 154.30M | 150.48M | 126.91M | 112.72M | 113.18M | 113.13M | 99.33M | 94.11M | 80.89M | 78.98M | 77.29M | 78.08M | 69.55M | 64.49M | 65.80M | 46.10M | 45.60M | 42.40M | 38.30M | 32.70M | 21.80M | 18.20M | 17.10M | 14.20M | 11.90M |
| Interest Income | 3.32M | 3.41M | 794.00K | 473.00K | 605.00K | 569.00K | 409.00K | 304.00K | 249.00K | 634.00K | 2.68M | 2.65M | 2.64M | 3.75M | 4.38M | 7.63M | 12.19M | 8.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.74M | 11.22M | 11.31M | 13.95M | 19.20M | 21.71M | 10.19M | 7.36M | 1.75M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.71M | 107.24M | 101.07M | 87.75M | 82.74M | 78.17M | 64.46M | 60.04M | 42.76M | 37.23M | 19.18M | 12.32M | 12.47M | 8.70M | 960.00K | 7.77M | 7.26M | 6.99M | 6.96M | 6.11M | 6.04M | 6.35M | 12.69M | 12.74M | 12.65M | 11.90M | 2.30M | 2.30M | 1.90M | 1.70M | 1.80M | 1.30M | 1.00M | 500.00K | 300.00K | 200.00K |
| EBITDA | 310.37M | 460.57M | 420.12M | 258.47M | 373.91M | 211.89M | 200.60M | 179.36M | 191.99M | 192.93M | 180.57M | 172.98M | 174.66M | 173.68M | 164.58M | 158.55M | 151.55M | 137.01M | 115.46M | 103.87M | 88.31M | 74.07M | 65.51M | 58.54M | 52.00M | 37.00M | 23.50M | 17.60M | 14.10M | 11.10M | 9.40M | 8.20M | 5.10M | 2.70M | 1.80M | 800.00K |
| EBITDA Ratio | 26.78% | 35.73% | 35.97% | 25.49% | 21.31% | 20.55% | 21.18% | 21.63% | 30.18% | 32.51% | 44.65% | 54.18% | 57.59% | 59.86% | 60.04% | 62.96% | 59.90% | 59.84% | 57.52% | 58.79% | 56.19% | 51.16% | 63.41% | 50.75% | 50.07% | 39.71% | 33.14% | 27.75% | 25.09% | 22.85% | 24.32% | 29.97% | 26.01% | 13.47% | 10.83% | 5.60% |
| Operating Income | 206.69M | 298.94M | 296.59M | 149.55M | 74.68M | 125.58M | 136.18M | 121.78M | 150.59M | 147.02M | 159.75M | 158.47M | 166.21M | 163.06M | 156.33M | 150.78M | 144.29M | 124.15M | 108.50M | 97.76M | 82.27M | 67.72M | 52.82M | 45.81M | 39.34M | 25.10M | 21.20M | 15.30M | 12.20M | 9.40M | 7.60M | 6.90M | 4.10M | 2.20M | 1.50M | 600.00K |
| Operating Income Ratio | 17.83% | 26.30% | 26.83% | 16.06% | 10.11% | 17.59% | 21.18% | 21.63% | 30.18% | 32.51% | 44.65% | 51.02% | 52.84% | 56.23% | 58.10% | 57.12% | 56.05% | 55.55% | 53.55% | 54.72% | 51.02% | 46.70% | 40.35% | 39.71% | 37.89% | 27.61% | 31.50% | 25.12% | 22.34% | 19.71% | 18.86% | 24.04% | 18.39% | 11.40% | 9.55% | 4.80% |
| Total Other Income/Expenses | -21.00M | 39.72M | 4.80M | -89.12M | 119.06M | -34.70M | -10.23M | -8.62M | -3.11M | 7.14M | 1.64M | 2.19M | -4.01M | 1.93M | 118.00K | 4.58M | 9.54M | 4.78M | 2.66M | 2.12M | 268.00K | 1.84M | -15.08M | 2.00M | 66.98K | 1.00M | 1.20M | 700.00K | 400.00K | 200.00K | -400.00K | -400.00K | -800.00K | 0.00 | -100.00K | 0.00 |
| Income Before Tax | 185.69M | 338.66M | 301.39M | 148.18M | 276.48M | 112.02M | 125.95M | 113.16M | 147.48M | 154.16M | 161.39M | 160.66M | 162.20M | 164.98M | 156.45M | 155.36M | 153.83M | 128.93M | 111.16M | 99.89M | 82.54M | 69.56M | 37.74M | 47.81M | 39.41M | 26.10M | 22.40M | 16.00M | 12.60M | 9.60M | 7.20M | 6.50M | 3.30M | 2.20M | 1.40M | 600.00K |
| Income Before Tax Ratio | 16.02% | 29.79% | 27.26% | 15.92% | 37.43% | 15.69% | 19.59% | 20.10% | 29.55% | 34.09% | 45.11% | 51.73% | 51.56% | 56.90% | 58.15% | 58.86% | 59.76% | 57.69% | 54.86% | 55.91% | 51.19% | 47.97% | 28.83% | 41.44% | 37.96% | 28.71% | 33.28% | 26.27% | 23.08% | 20.13% | 17.87% | 22.65% | 14.80% | 11.40% | 8.92% | 4.80% |
| Income Tax Expense | 17.58M | 53.22M | 38.29M | 8.59M | 47.18M | 15.94M | 602.00K | 35.88M | 43.01M | 46.43M | 50.44M | 48.10M | 49.86M | 52.68M | 46.67M | 50.12M | 50.27M | 43.82M | 37.81M | 33.76M | 29.61M | 24.16M | 10.61M | 13.76M | 12.83M | 9.40M | 7.20M | 5.10M | 4.00M | 2.90M | 2.10M | 2.10M | 1.30M | 600.00K | 400.00K | 200.00K |
| Net Income | 168.11M | 285.26M | 272.05M | 140.41M | 229.30M | 96.07M | 125.35M | 77.29M | 104.48M | 107.74M | 110.95M | 112.56M | 112.33M | 112.30M | 109.78M | 105.24M | 103.56M | 85.11M | 73.35M | 66.13M | 52.93M | 45.40M | 27.13M | 34.05M | 26.58M | 16.70M | 15.20M | 10.90M | 8.60M | 6.70M | 5.10M | 4.40M | 2.00M | 1.60M | 1.00M | 400.00K |
| Net Income Ratio | 14.50% | 25.10% | 24.61% | 15.08% | 31.04% | 13.46% | 19.49% | 13.73% | 20.94% | 23.82% | 31.01% | 36.24% | 35.71% | 38.73% | 40.80% | 39.87% | 40.23% | 38.08% | 36.20% | 37.02% | 32.82% | 31.31% | 20.73% | 29.51% | 25.60% | 18.37% | 22.59% | 17.90% | 15.75% | 14.05% | 12.66% | 15.33% | 8.97% | 8.29% | 6.37% | 3.20% |
| EPS | 1.07 | 1.81 | 1.73 | 0.91 | 1.50 | 0.64 | 0.84 | 0.52 | 0.70 | 0.73 | 0.75 | 0.76 | 0.76 | 0.76 | 0.74 | 0.70 | 0.66 | 0.54 | 0.47 | 0.41 | 0.32 | 0.27 | 0.16 | 0.21 | 0.16 | 0.10 | 0.10 | 0.07 | 0.06 | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 |
| EPS Diluted | 1.05 | 1.76 | 1.66 | 0.87 | 1.45 | 0.62 | 0.82 | 0.52 | 0.70 | 0.72 | 0.75 | 0.76 | 0.76 | 0.76 | 0.73 | 0.69 | 0.66 | 0.54 | 0.46 | 0.40 | 0.32 | 0.27 | 0.16 | 0.20 | 0.16 | 0.10 | 0.10 | 0.07 | 0.06 | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 157.71M | 157.18M | 156.88M | 154.99M | 152.80M | 151.12M | 149.90M | 149.25M | 148.78M | 148.38M | 147.56M | 147.34M | 147.76M | 148.39M | 149.02M | 151.21M | 156.56M | 157.62M | 156.20M | 161.44M | 164.18M | 165.48M | 166.03M | 165.75M | 162.50M | 160.94M | 151.62M | 150.34M | 155.54M | 152.35M | 145.71M | 146.67M | 133.33M | 128.00M | 133.33M | 126.14M |
| Weighted Avg Shares Out (Dil) | 160.77M | 161.86M | 164.12M | 161.93M | 157.60M | 155.57M | 152.22M | 150.00M | 149.30M | 148.92M | 148.02M | 147.60M | 148.02M | 148.69M | 149.39M | 151.60M | 156.99M | 158.05M | 158.38M | 163.68M | 166.79M | 168.12M | 170.09M | 170.67M | 168.82M | 165.49M | 156.86M | 155.71M | 155.54M | 153.33M | 145.71M | 146.67M | 133.33M | 128.00M | 133.33M | 126.14M |
What to Expect From These 3 MedTech Stocks This Earnings Season
Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.
ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics
ST. PAUL, Minn. , Oct. 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH), today announced that Luminary Therapeutics has been awarded a $300,000 G-Rex® Grant.
LINCOLN TECH ANNOUNCES PARTNERSHIP WITH HYUNDAI MOTOR AMERICA & GENESIS MOTOR AMERICA; TRAINING OFFERED AT NO ADDITIONAL COST TO STUDENTS
New career training option will help meet growing nationwide demand for Hyundai and Genesis automotive technicians. New career training option will help meet growing nationwide demand for Hyundai and Genesis automotive technicians.
CYBER ENVIRO-TECH INC ANNOUNCES PARTNERSHIP WITH SOME OF ITS SHAREHOLDERS TO FOCUS ON THE LAUNDRY INDUSTRY
SCOTTSDALE, Ariz. , Oct. 10, 2024 /PRNewswire/ -- Cyber Enviro-Tech Inc. (CETI) (OTCQB: CETI) CETI, is pleased to announce a partnership with its shareholder-based subsidiary, CETI Axenic (CAX), to pursue opportunities in the commercial laundry business.
BIO-TECHNE TO HOST CONFERENCE CALL ON OCTOBER 30, 2024, TO ANNOUNCE FIRST QUARTER FISCAL 2025 FINANCIAL RESULTS
MINNEAPOLIS , Oct. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, October 30, 2024, at 8:00 a.m. CDT to review its first quarter fiscal 2025 financial results.
ACAD or TECH: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Acadia Pharmaceuticals (ACAD) and Techne (TECH). But which of these two stocks is more attractive to value investors?
ScaleReady announces a G-Rex® Grant has been awarded to LIfT Biosciences
Award will support clinical manufacturing of the Company's promising Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform ST. PAUL, Minn.
ScaleReady announces a G-Rex® Grant has been awarded to Dr. Eric Tran of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute
ST. PAUL, Minn. , Oct. 8, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Eric Tran, Ph.D, Associate Member of the Earle A.
ScaleReady announces a G-Rex® Grant has been awarded to renowned cancer immunologist Dr. Christopher A. Klebanoff
ST. PAUL, Minn. , Oct. 7, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Christopher A.
ALPHA PRO TECH, LTD. ANNOUNCES $1 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM FOR IMMEDIATE RELEASE
NOGALES, Ariz., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced that its Board of...
Source: https://incomestatements.info
Category: Stock Reports